Skip to main content
Body

Race as a Social Construct: Serving the Needs of All Individuals

 

Race is a social construct that is broadly used to categorize people based on physical characteristics, behavioral patterns, and geographic location. Race is not a proxy for biology or genetics. Data regarding race is typically based on self-identification and data collection routinely allows respondents to select more than one race. Racial and ethnic groups that have historically faced discrimination are at a higher risk for cardiovascular disease and diabetes. Ohio Department of Medicaid recognizes that social inequality, not genetic differences, produce these racial and ethnic health disparities. Examining health access, health care quality, and health outcome data by race and ethnicity allows the health system to assist in addressing the factors contributing to inequity and ensure that the health system serves the needs of all individuals. October 2021

For more information, please contact Melissa Nance, ODM Quality Improvement Section Chief (Melissa.Nance@medicaid.ohio.gov).


 

  • crop_skinny.png
    Learn More
  • crop_skinny.png
    Watch Recording
  • crop_skinny.png
    Sharing Best Practices to Improve
    Cardiovascular and Diabetes Health
  • crop_skinny.png
    Capsules
  • crop_skinny_0.png
    Featured Teams
  • crop_skinny_2.png
    Accurate Blood Pressure
    Measurement
  • crop_skinny.png
    Listen Now

Sharing best practices to improve cardiovascular and diabetes health.

 
Founded in 2017, the mission of Cardi-OH is to improve cardiovascular and diabetes health outcomes and eliminate disparities in Ohio's Medicaid population.

 

 
Body

MOST RECENT

Study Shows Efpeglenatide Lowers Cardiovascular Disease Risk in High-Risk Patients with Type 2 Diabetes

The June 2021 AMPLITUDE-O study evaluated the use of efpeglenatide in patients with type 2 diabetes mellitus who had either a history of cardiovascular (CV) disease or current kidney disease plus one additional CV risk factor. This randomized controlled trial evaluated CV risk reduction in patients taking weekly subcutaneous injections of efpeglenatide, a novel exendin-based glucagon-like peptide-1 receptor agonist (GLP-1 RA). Prior studies established CV risk reduction properties of analogs to human GLP-1; however, a dedicated outcomes trial of another exendin-based molecule (exenatide once weekly) did not demonstrate CV benefit which raised concerns that the CV benefit from GLP-1-based therapies was not a class effect.

READ MORE →

Body
What We Do

What We Do


Experts at Ohio's seven medical schools identify, produce, and disseminate the latest evidence-based cardiovascular and diabetes best practices.

 

How We Do It Icon

 

 

How We Do It


Utilize monthly newsletters and an online repository of resources at Cardi-OH.org, podcasts available on Cardi-OH Radio, and the Project ECHO® virtual training model.

Why We Do It

Why We Do It


To improve the health and well-being of all Ohioans.

Body

 
Body

 

© 2020 Cardi-OH

 

Body
Body